The Institute of Molecular Oncology/University Medical Center Göttingen, laboratory of Dr. Ramona Schulz-Heddergott, is looking for a highly motivated
PhD student (m/f/d) Molecular Oncology
3 years, part time (50%) | salary according to TV-L
The University Medical Center Göttingen is a tertiary care center and offers great development potential. Its 7,900 employees work in over 65 departments and facilities to provide top-quality patient care, excellent research and modern teaching. Göttingen, “City of Science”, located near the center of Germany, the University Medical Center Göttingen is embedded in the city’s attractive network of scientific research facilities.
The position is funded by the German Research Foundation (DFG) and offers a TV-L E13 (50%) salary. The position is situated within the clinical research unit KF05002 and available from 1 April 2021.
Our group studies the oncogenic impact of the tumoral chaperone system including their stabilized oncogenes such as mutated p53 variants in colorectal cancer and pancreatic cancer. Mutant p53 variants differ in their regulatory capacity and there is a strong need to understand single p53 mutant variants on its own. Another research focus is how mutated p53 variants are stabilized by the chaperone machinery, and how we can target such oncogenic proteins. We are based on our bench-to-bedside interest - translational research, we test our in vitro findings in experimental cancer mouse models and in samples from human patients.
Methods that will be used:
- In vivo experiments: cancer mouse model, colonoscopy, drug application, organ isolation and generation of organoid cultures
- Histology: micro- and cryotomy, immunohistochemical staining, light and fluorescence microscopy
- Molecular and cellular biology: a broad range including PCR, qPCR, RNA-seq,Immunoblotting, proliferation/viability/growth assays, migration assays etc.
Isermann et al. 2021. Suppression of HSF1 activity by wildtype p53 creates a driving force for p53 loss-of-heterozygosity. Under consideration in Nature Communications, Published Apr 27, 2020.
Klemke et al. 2021. Hsp90-stabilized MIF supports tumor progression via macrophage recruitment and angiogenesis in colorectal cancer. Cell Death Dis. 2021. In press.
Schulz-Heddergott et al, 2018. Therapeutic ablation of gain-of-function mutant p53 in colorectal cancer inhibits Stat3-mediated tumor growth and invasion. Cancer Cell. 34(2):298-314.
The successful candidate will hold a qualified diploma or M.Sc. in biology, biochemistry or related fields, with a strong background in oncology or related topics and is experienced in cell culture techniques, molecular biology and cell biology. The ideal candidate is proficient in or at least prepared to working with engineered mouse models.
We are looking for an exceptionally motivated, pro-active and team-orientated candidate who excels in the challenge of being in a dynamic and very productive research team.
We offer a PhD position with salary according to TV-L E13/50%.
The candidate will be working in an innovative, well-equipped and scientifically stimulating surrounding.
The involvement in graduate PhD programs at the University of Göttingen, such as the Graduiertenschule GGNB.
Women are especially encouraged to apply. Applicants with disabilities and equal qualifications will be given preferential treatment.
We look forward to receiving your application by February 28th, 2021:
University Medical Center Göttingen
Institute of Molecular Oncology
Dr. Ramona Schulz-Heddergott
Dr. Ramona Schulz-Heddergott
Please send your application only via e-mail as a PDF-file.
Travel and application fees cannot be refunded or transferred.